New agents and strategies for the hormonal treatment of castration-resistant prostate cancer

Bibliography

• Jemal A, Siegel R, Ward E, Cancer statistics, 2009. CA Cancer J Clin 2009;19(4):225-49
   Google Scholar
• Walsh PC, DeWeese TL, Eisenberger MA. Clinical practice. Localized prostate cancer. N Engl J Med 2007;357(26):2696-705
   PubMedGoogle Scholar
• Huggins C, Hodges CV. Studies on prostate cancer, I: the effect of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-7
   Google Scholar
• Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005;294(2):238-44
   PubMed Web of Science ®Google Scholar
• Tolis G, Ackman D, Stellos A, Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci USA 1982;79(5):1658-62
   PubMed Web of Science ®Google Scholar
• Klotz L, Boccon-Gibod L, Shore ND, The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008;102(11):1531-8
   PubMed Web of Science ®Google Scholar
• Bubley GJ, Carducci M, Dahut W, Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17(11):3461-7
   PubMed Web of Science ®Google Scholar
• Page ST, Lin DW, Mostaghel EA, Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 2006;91(10):3850-6
   PubMed Web of Science ®Google Scholar
• Mostaghel EA, Page ST, Lin DW, Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 2007;67(10):5033-41
   PubMed Web of Science ®Google Scholar
• Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 2000;355(9214):1491-8
   PubMed Web of Science ®Google Scholar
• Taplin ME. Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol 2007;4(4):236-44
   PubMedGoogle Scholar
• Sharifi N, Dahut WL, Figg WD. Secondary hormonal therapy for prostate cancer: what lies on the horizon? BJU Int 2008;101(3):271-4
   PubMed Web of Science ®Google Scholar
• Gao W, Bohl CE, Dalton JT. Chemistry and structural biology of androgen receptor. Chem Rev 2005;105(9):3352-70
   PubMed Web of Science ®Google Scholar
• Gardner DG, Shoback D. Greenspan's basic and clinical endocrinology. 8th edition. McGraw-Hill, San Francisco, USA; 2007
   Google Scholar
• De Coster R, Wouters W, Bruynseels J. P450-dependent enzymes as targets for prostate cancer therapy. J Steroid Biochem Mol Biol 1996;56(1-6 Spec No):133-43
   PubMed Web of Science ®Google Scholar
• Reid AH, Attard G, Barrie E, de Bono JS. CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol 2008;5(11):610-20
   PubMedGoogle Scholar
• Santen RJ, Van den Bossche H, Symoens J, Site of action of low dose ketoconazole on androgen biosynthesis in men. J Clin Endocrinol Metab 1983;57(4):732-6
   PubMed Web of Science ®Google Scholar
• Pont A, Williams PL, Azhar S, Ketoconazole blocks testosterone synthesis. Arch Intern Med 1982;142(12):2137-40
   PubMed Web of Science ®Google Scholar
• Figg WD, Liu Y, Arlen P, A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. J Urol 2005;173(3):790-6
   PubMed Web of Science ®Google Scholar
• Mousses S, Wagner U, Chen Y, Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene 2001;20(46):6718-23
   PubMed Web of Science ®Google Scholar
• Holzbeierlein J, Lal P, LaTulippe E, Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164(1):217-27
   PubMed Web of Science ®Google Scholar
• Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23(32):8253-61
   PubMed Web of Science ®Google Scholar
• McPhaul MJ. Mechanisms of prostate cancer progression to androgen independence. Best Pract Res Clin Endocrinol Metab 2008;22(2):373-88
   PubMed Web of Science ®Google Scholar
• Chen CD, Welsbie DS, Tran C, Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10(1):33-9
   PubMed Web of Science ®Google Scholar
• Bubendorf L, Kononen J, Koivisto P, Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 1999;59(4):803-6
   PubMed Web of Science ®Google Scholar
• Edwards J, Krishna NS, Grigor KM, Bartlett JM. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003;89(3):552-6
   PubMed Web of Science ®Google Scholar
• Leversha MA, Han J, Asgari Z, Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res 2009;15(6):2091-7
   PubMed Web of Science ®Google Scholar
• Veldscholte J, Ris-Stalpers C, Kuiper GG, A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990;173(2):534-40
   PubMed Web of Science ®Google Scholar
• Steinkamp MP, O'Mahony OA, Brogley M, Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res 2009;69(10):4434-42
   PubMed Web of Science ®Google Scholar
• Dehm SM, Schmidt LJ, Heemers HV, Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008;68(13):5469-77
   PubMed Web of Science ®Google Scholar
• Hu R, Dunn TA, Wei S, Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009;69(1):16-22
   PubMed Web of Science ®Google Scholar
• Guo Z, Yang X, Sun F, A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009;69(6):2305-13
   PubMed Web of Science ®Google Scholar
• Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview. Endocr Rev 2002;23(2):175-200
   PubMed Web of Science ®Google Scholar
• Ponguta LA, Gregory CW, French FS, Wilson EM. Site-specific androgen receptor serine phosphorylation linked to epidermal growth factor-dependent growth of castration-recurrent prostate cancer. J Biol Chem 2008;283(30):20989-1001
   PubMed Web of Science ®Google Scholar
• Weber MJ, Gioeli D. Ras signaling in prostate cancer progression. J Cell Biochem 2004;91(1):13-25
   PubMed Web of Science ®Google Scholar
• Geller J, Albert J, Loza D, DHT concentrations in human prostate cancer tissue. J Clin Endocrinol Metab 1978;46(3):440-4
   PubMed Web of Science ®Google Scholar
• Titus MA, Schell MJ, Lih FB, Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005;11(13):4653-7
   PubMed Web of Science ®Google Scholar
• Montgomery RB, Mostaghel EA, Vessella R, Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68(11):4447-54
   PubMed Web of Science ®Google Scholar
• Miller WL. Mechanism of StAR's regulation of mitochondrial cholesterol import. Mol Cell Endocrinol 2007;265-266:46-50
   PubMed Web of Science ®Google Scholar
• Auchus RJ. Overview of dehydroepiandrosterone biosynthesis. Semin Reprod Med 2004;22(4):281-8
   PubMed Web of Science ®Google Scholar
• Miller WL, Auchus RJ, Geller DH. The regulation of 17,20 lyase activity. Steroids 1997;62(1):133-42
   PubMed Web of Science ®Google Scholar
• Wilson JD, Auchus RJ, Leihy MW, 5alpha-androstane-3alpha,17beta-diol is formed in tammar wallaby pouch young testes by a pathway involving 5alpha-pregnane-3alpha,17alpha-diol-20-one as a key intermediate. Endocrinology 2003;144(2):575-80
   PubMed Web of Science ®Google Scholar
• Gupta MK, Guryev OL, Auchus RJ. 5alpha-reduced C21 steroids are substrates for human cytochrome P450c17. Arch Biochem Biophys 2003;418(2):151-60
   PubMed Web of Science ®Google Scholar
• Kater CE, Biglieri EG. Disorders of steroid 17 alpha-hydroxylase deficiency. Endocrinol Metab Clin North Am 1994;23(2):341-57
   PubMed Web of Science ®Google Scholar
• Moeller G, Adamski J. Integrated view on 17beta-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 2009;301(1-2):7-19
   PubMed Web of Science ®Google Scholar
• Khan N, Sharma KK, Andersson S, Auchus RJ. Human 17beta-hydroxysteroid dehydrogenases types 1, 2, and 3 catalyze bi-directional equilibrium reactions, rather than unidirectional metabolism, in HEK-293 cells. Arch Biochem Biophys 2004;429(1):50-9
   PubMed Web of Science ®Google Scholar
• Adams JB. Control of secretion and the function of C19-delta 5-steroids of the human adrenal gland. Mol Cell Endocrinol 1985;41(1):1-17
   PubMed Web of Science ®Google Scholar
• Mizokami A, Koh E, Fujita H, The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 2004;64(2):765-71
   PubMed Web of Science ®Google Scholar
• Miyamoto H, Yeh S, Lardy H, Delta5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells. Proc Natl Acad Sci USA 1998;95(19):11083-8
   PubMed Web of Science ®Google Scholar
• Tan J, Sharief Y, Hamil KG, Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 1997;11(4):450-9
   PubMed Web of Science ®Google Scholar
• Arnold JT, Blackman MR. Does DHEA exert direct effects on androgen and estrogen receptors, and does it promote or prevent prostate cancer? Endocrinology 2005;146(11):4565-7
   PubMed Web of Science ®Google Scholar
• Lorence MC, Murry BA, Trant JM, Mason JI. Human 3 beta-hydroxysteroid dehydrogenase/delta 5- - - -4isomerase from placenta: expression in nonsteroidogenic cells of a protein that catalyzes the dehydrogenation/isomerization of C21 and C19 steroids. Endocrinology 1990;126(5):2493-8
   PubMed Web of Science ®Google Scholar
• Simard J, Ricketts ML, Gingras S, Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family. Endocr Rev 2005;26(4):525-82
   PubMed Web of Science ®Google Scholar
• Cai C, Wang H, Xu Y, Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Res 2009;69(15):6027-32
   PubMed Web of Science ®Google Scholar
• Locke JA, Nelson CC, Adomat HH, Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts. J Steroid Biochem Mol Biol 2009;115(3-5):126-36
   PubMed Web of Science ®Google Scholar
• Luu-The V, Belanger A, Labrie F. Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrinol Metab 2008;22(2):207-21
   PubMed Web of Science ®Google Scholar
• Andersson S, Geissler WM, Wu L, Molecular genetics and pathophysiology of 17 beta-hydroxysteroid dehydrogenase 3 deficiency. J Clin Endocrinol Metab 1996;81(1):130-6
   PubMed Web of Science ®Google Scholar
• Andersson S, Russell DW, Wilson JD. 17beta-Hydroxysteroid dehydrogenase 3 deficiency. Trends Endocrinol Metab 1996;7(4):121-6
   PubMed Web of Science ®Google Scholar
• Dufort I, Rheault P, Huang XF, Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase. Endocrinology 1999;140(2):568-74
   PubMed Web of Science ®Google Scholar
• Labrie F, Luu-The V, Lin SX, The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology. Steroids 1997;62(1):148-58
   PubMed Web of Science ®Google Scholar
• Penning TM, Byrns MC. Steroid hormone transforming aldo-keto reductases and cancer. Ann NY Acad Sci 2009;1155:33-42
   PubMed Web of Science ®Google Scholar
• Wilson JD. The role of 5alpha-reduction in steroid hormone physiology. Reprod Fertil Dev 2001;13(7-8):673-8
   PubMed Web of Science ®Google Scholar
• Russell DW, Wilson JD. Steroid 5 alpha-reductase: two genes/two enzymes. Annu Rev Biochem 1994;63:25-61
   PubMed Web of Science ®Google Scholar
• Andersson S, Russell DW. Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha-reductases. Proc Natl Acad Sci USA 1990;87(10):3640-4
   PubMed Web of Science ®Google Scholar
• Andersson S, Berman DM, Jenkins EP, Russell DW. Deletion of steroid 5 alpha-reductase 2 gene in male pseudohermaphroditism. Nature 1991;354(6349):159-61
   PubMed Web of Science ®Google Scholar
• Thomas LN, Douglas RC, Lazier CB, Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. Eur Urol 2008;53(2):244-52
   PubMed Web of Science ®Google Scholar
• Thomas LN, Lazier CB, Gupta R, Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 2005;63(3):231-9
   PubMed Web of Science ®Google Scholar
• Titus MA, Gregory CW, Ford OH III, Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 2005;11(12):4365-71
   PubMed Web of Science ®Google Scholar
• Xu Y, Dalrymple SL, Becker RE, Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res 2006;12(13):4072-9
   PubMed Web of Science ®Google Scholar
• George FW, Russell DW, Wilson JD. Feed-forward control of prostate growth: dihydrotestosterone induces expression of its own biosynthetic enzyme, steroid 5 alpha-reductase. Proc Natl Acad Sci USA 1991;88(18):8044-7
   PubMed Web of Science ®Google Scholar
• Penning TM, Jin Y, Rizner TL, Bauman DR. Pre-receptor regulation of the androgen receptor. Mol Cell Endocrinol 2008;281(1-2):1-8
   PubMed Web of Science ®Google Scholar
• Rizner TL, Lin HK, Peehl DM, Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells. Endocrinology 2003;144(7):2922-32
   PubMed Web of Science ®Google Scholar
• Barbier O, Belanger A. Inactivation of androgens by UDP-glucuronosyltransferases in the human prostate. Best Pract Res Clin Endocrinol Metab 2008;22(2):259-70
   PubMed Web of Science ®Google Scholar
• Belanger A, Candas B, Dupont A, Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. J Clin Endocrinol Metab 1994;79(4):1086-90
   PubMed Web of Science ®Google Scholar
• Bruchovsky N, Wilson JD. Discovery of the role of dihydrotestosterone in androgen action. Steroids 1999;64(11):753-9
   PubMed Web of Science ®Google Scholar
• Barrie SE, Potter GA, Goddard PM, Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 1994;50(5-6):267-73
   PubMed Web of Science ®Google Scholar
• O'Donnell A, Judson I, Dowsett M, Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004;90(12):2317-25
   PubMed Web of Science ®Google Scholar
• Attard G, Reid AH, Yap TA, Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;26(28):4563-71
   PubMed Web of Science ®Google Scholar
• Attard G, Reid AH, A'Hern R, Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009;27(23):3742-8
   PubMed Web of Science ®Google Scholar
• Leon CG, Locke JA, Adomat HH, Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate 2009
   Web of Science ®Google Scholar
• Attard G, Cooper CS, de Bono JS. Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 2009;16(6):458-62
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, Fong L, Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010;28(9):1481-8
   PubMed Web of Science ®Google Scholar
• Small EJ, Halabi S, Dawson NA, Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004;22(6):1025-33
   PubMed Web of Science ®Google Scholar
• Danila DC, Morris MJ, de Bono JS, Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010;28(9):1496-501
   PubMed Web of Science ®Google Scholar
• Reid AH, Attard G, Danila DC, Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010;28(9):1489-95
   PubMed Web of Science ®Google Scholar
• Tran C, Ouk S, Clegg NJ, Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324(5928):787-90
   PubMed Web of Science ®Google Scholar
• Scher HI, Beer TM, Higano CS, Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375(9724):1437-46
   PubMed Web of Science ®Google Scholar
• Handratta VD, Vasaitis TS, Njar VC, Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J Med Chem 2005;48(8):2972-84
   PubMed Web of Science ®Google Scholar
• Vasaitis T, Belosay A, Schayowitz A, Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol Cancer Ther 2008;7(8):2348-57
   PubMed Web of Science ®Google Scholar
• Bruno RD, Gover TD, Burger AM, 17alpha-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response. Mol Cancer Ther 2008;7(9):2828-36
   PubMed Web of Science ®Google Scholar
• Evaul K, Li R, Papari-Zareei M, 3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer. Endocrinology [In press]
   PubMedGoogle Scholar
• Auchus RJ. The backdoor pathway to dihydrotestosterone. Trends Endocrinol Metab 2004;15(9):432-8
   PubMed Web of Science ®Google Scholar
• Takahashi M, Luu-The V, Labrie F. Inhibitory effect of synthetic progestins, 4-MA and cyanoketone on human placental 3 beta-hydroxysteroid dehydrogenase/5–4-ene-isomerase activity. J Steroid Biochem Mol Biol 1990;37(2):231-6
   PubMed Web of Science ®Google Scholar
• Thomas JL, Mason JI, Brandt S, Norris W. Differences in substrate and inhibitor kinetics of human type 1 and type 2 3beta-hydroxysteroid dehydrogenase are explained by the type 1 mutant, H156Y. Endocr Res 2002;28(4):471-5
   PubMed Web of Science ®Google Scholar
• Crooij MJ, de Nooyer CC, Rao BR, Termination of early pregnancy by the 3 beta-hydroxysteroid dehydrogenase inhibitor epostane. N Engl J Med 1988;319(13):813-7
   PubMed Web of Science ®Google Scholar
• Mizokami A, Koh E, Izumi K, Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone. Endocr Relat Cancer 2009;16(4):1139-55
   PubMed Web of Science ®Google Scholar
• Stanbrough M, Bubley GJ, Ross K, Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66(5):2815-25
   PubMed Web of Science ®Google Scholar
• Penning TM, Steckelbroeck S, Bauman DR, Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors. Mol Cell Endocrinol 2006;248(1-2):182-91
   PubMed Web of Science ®Google Scholar
• Byrns MC, Steckelbroeck S, Penning TM. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies. Biochem Pharmacol 2008;75(2):484-93
   PubMed Web of Science ®Google Scholar
• Byrns MC, Penning TM. Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact 2009;178(1-3):221-7
   PubMed Web of Science ®Google Scholar
• Taplin ME, Regan MM, Ko YJ, Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res 2009;15(22):7099-105
   PubMed Web of Science ®Google Scholar
• Sartor O, Nakabayashi M, Taplin ME, Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone. Clin Genitourin Cancer 2009;7(3):E90-2
   PubMed Web of Science ®Google Scholar